WEBVTT
Kind: captions
Language: en

00:00:05.660 --> 00:00:08.299
like to welcome our first speaker dr.

00:00:08.299 --> 00:00:08.309
like to welcome our first speaker dr.
 

00:00:08.309 --> 00:00:11.990
like to welcome our first speaker dr.
Harry Auster he runs the is the director

00:00:11.990 --> 00:00:12.000
Harry Auster he runs the is the director
 

00:00:12.000 --> 00:00:14.900
Harry Auster he runs the is the director
of the human genome program human

00:00:14.900 --> 00:00:14.910
of the human genome program human
 

00:00:14.910 --> 00:00:17.060
of the human genome program human
genetics program at NYU Medical School

00:00:17.060 --> 00:00:17.070
genetics program at NYU Medical School
 

00:00:17.070 --> 00:00:19.760
genetics program at NYU Medical School
he is a professor of pediatrics

00:00:19.760 --> 00:00:19.770
he is a professor of pediatrics
 

00:00:19.770 --> 00:00:22.160
he is a professor of pediatrics
pathology and medicine there and he's a

00:00:22.160 --> 00:00:22.170
pathology and medicine there and he's a
 

00:00:22.170 --> 00:00:24.050
pathology and medicine there and he's a
wide range of interests which he's

00:00:24.050 --> 00:00:24.060
wide range of interests which he's
 

00:00:24.060 --> 00:00:26.720
wide range of interests which he's
pursued in his laboratory he's worked on

00:00:26.720 --> 00:00:26.730
pursued in his laboratory he's worked on
 

00:00:26.730 --> 00:00:28.820
pursued in his laboratory he's worked on
the genetics of prostate cancer and

00:00:28.820 --> 00:00:28.830
the genetics of prostate cancer and
 

00:00:28.830 --> 00:00:31.510
the genetics of prostate cancer and
other forms of cancer he's worked on

00:00:31.510 --> 00:00:31.520
other forms of cancer he's worked on
 

00:00:31.520 --> 00:00:34.459
other forms of cancer he's worked on
genetics of ancestry particularly in

00:00:34.459 --> 00:00:34.469
genetics of ancestry particularly in
 

00:00:34.469 --> 00:00:36.979
genetics of ancestry particularly in
Jewish and Latino populations he's

00:00:36.979 --> 00:00:36.989
Jewish and Latino populations he's
 

00:00:36.989 --> 00:00:39.920
Jewish and Latino populations he's
worked on the genetics of male sexual

00:00:39.920 --> 00:00:39.930
worked on the genetics of male sexual
 

00:00:39.930 --> 00:00:42.470
worked on the genetics of male sexual
development and he's been very involved

00:00:42.470 --> 00:00:42.480
development and he's been very involved
 

00:00:42.480 --> 00:00:45.080
development and he's been very involved
in issues involving the fair use of

00:00:45.080 --> 00:00:45.090
in issues involving the fair use of
 

00:00:45.090 --> 00:00:47.150
in issues involving the fair use of
genetic information and in that capacity

00:00:47.150 --> 00:00:47.160
genetic information and in that capacity
 

00:00:47.160 --> 00:00:50.330
genetic information and in that capacity
he's been an advisor to the National

00:00:50.330 --> 00:00:50.340
he's been an advisor to the National
 

00:00:50.340 --> 00:00:52.160
he's been an advisor to the National
Institutes of Health has been advisor

00:00:52.160 --> 00:00:52.170
Institutes of Health has been advisor
 

00:00:52.170 --> 00:00:54.470
Institutes of Health has been advisor
the Defense Department and the New York

00:00:54.470 --> 00:00:54.480
the Defense Department and the New York
 

00:00:54.480 --> 00:00:56.569
the Defense Department and the New York
Bar Association here in New York in

00:00:56.569 --> 00:00:56.579
Bar Association here in New York in
 

00:00:56.579 --> 00:00:58.459
Bar Association here in New York in
which he's been involved in every piece

00:00:58.459 --> 00:00:58.469
which he's been involved in every piece
 

00:00:58.469 --> 00:01:01.069
which he's been involved in every piece
of legislation that's pending or enacted

00:01:01.069 --> 00:01:01.079
of legislation that's pending or enacted
 

00:01:01.079 --> 00:01:04.100
of legislation that's pending or enacted
that has to do with genetic testing with

00:01:04.100 --> 00:01:04.110
that has to do with genetic testing with
 

00:01:04.110 --> 00:01:06.380
that has to do with genetic testing with
reproductive technology and human

00:01:06.380 --> 00:01:06.390
reproductive technology and human
 

00:01:06.390 --> 00:01:19.530
reproductive technology and human
cloning so welcome dr. Auster

00:01:19.530 --> 00:01:19.540
 

00:01:19.540 --> 00:01:22.180
so I'd like to thank Paul Hoffman and

00:01:22.180 --> 00:01:22.190
so I'd like to thank Paul Hoffman and
 

00:01:22.190 --> 00:01:25.570
so I'd like to thank Paul Hoffman and
his fellow organizers of big think for

00:01:25.570 --> 00:01:25.580
his fellow organizers of big think for
 

00:01:25.580 --> 00:01:27.430
his fellow organizers of big think for
inviting me to participate this evening

00:01:27.430 --> 00:01:27.440
inviting me to participate this evening
 

00:01:27.440 --> 00:01:30.820
inviting me to participate this evening
as Francis Collins understudied this

00:01:30.820 --> 00:01:30.830
as Francis Collins understudied this
 

00:01:30.830 --> 00:01:32.710
as Francis Collins understudied this
invitation has left me wondering what

00:01:32.710 --> 00:01:32.720
invitation has left me wondering what
 

00:01:32.720 --> 00:01:34.690
invitation has left me wondering what
whether there might be an NIH

00:01:34.690 --> 00:01:34.700
whether there might be an NIH
 

00:01:34.700 --> 00:01:37.480
whether there might be an NIH
directorship in my future or whether

00:01:37.480 --> 00:01:37.490
directorship in my future or whether
 

00:01:37.490 --> 00:01:39.219
directorship in my future or whether
I'll be left with the happy fate of

00:01:39.219 --> 00:01:39.229
I'll be left with the happy fate of
 

00:01:39.229 --> 00:01:41.530
I'll be left with the happy fate of
being a medical geneticist free to

00:01:41.530 --> 00:01:41.540
being a medical geneticist free to
 

00:01:41.540 --> 00:01:44.560
being a medical geneticist free to
pursue my own research leads there are

00:01:44.560 --> 00:01:44.570
pursue my own research leads there are
 

00:01:44.570 --> 00:01:47.050
pursue my own research leads there are
three areas that I currently explore the

00:01:47.050 --> 00:01:47.060
three areas that I currently explore the
 

00:01:47.060 --> 00:01:49.240
three areas that I currently explore the
first is the genetic control of male

00:01:49.240 --> 00:01:49.250
first is the genetic control of male
 

00:01:49.250 --> 00:01:52.810
first is the genetic control of male
sexual development normally a switch on

00:01:52.810 --> 00:01:52.820
sexual development normally a switch on
 

00:01:52.820 --> 00:01:55.420
sexual development normally a switch on
the Y chromosome turns on a pathway that

00:01:55.420 --> 00:01:55.430
the Y chromosome turns on a pathway that
 

00:01:55.430 --> 00:01:58.510
the Y chromosome turns on a pathway that
causes half of us in the population to

00:01:58.510 --> 00:01:58.520
causes half of us in the population to
 

00:01:58.520 --> 00:02:00.790
causes half of us in the population to
develop testes male reproductive

00:02:00.790 --> 00:02:00.800
develop testes male reproductive
 

00:02:00.800 --> 00:02:04.300
develop testes male reproductive
structures and to develop as men but the

00:02:04.300 --> 00:02:04.310
structures and to develop as men but the
 

00:02:04.310 --> 00:02:07.480
structures and to develop as men but the
switch or its downstream relays may go

00:02:07.480 --> 00:02:07.490
switch or its downstream relays may go
 

00:02:07.490 --> 00:02:09.699
switch or its downstream relays may go
awry causing affected individuals to

00:02:09.699 --> 00:02:09.709
awry causing affected individuals to
 

00:02:09.709 --> 00:02:12.250
awry causing affected individuals to
develop as women or to have ambiguous

00:02:12.250 --> 00:02:12.260
develop as women or to have ambiguous
 

00:02:12.260 --> 00:02:15.640
develop as women or to have ambiguous
sexual development these people with

00:02:15.640 --> 00:02:15.650
sexual development these people with
 

00:02:15.650 --> 00:02:18.789
sexual development these people with
disorders of sexual development present

00:02:18.789 --> 00:02:18.799
disorders of sexual development present
 

00:02:18.799 --> 00:02:20.590
disorders of sexual development present
the experiments of nature that we

00:02:20.590 --> 00:02:20.600
the experiments of nature that we
 

00:02:20.600 --> 00:02:23.500
the experiments of nature that we
geneticists so value because they

00:02:23.500 --> 00:02:23.510
geneticists so value because they
 

00:02:23.510 --> 00:02:24.880
geneticists so value because they
represent an opportunity for

00:02:24.880 --> 00:02:24.890
represent an opportunity for
 

00:02:24.890 --> 00:02:27.130
represent an opportunity for
understanding the whole cascade of genes

00:02:27.130 --> 00:02:27.140
understanding the whole cascade of genes
 

00:02:27.140 --> 00:02:29.470
understanding the whole cascade of genes
in the male sexual development pathway

00:02:29.470 --> 00:02:29.480
in the male sexual development pathway
 

00:02:29.480 --> 00:02:33.880
in the male sexual development pathway
in my lab we've recently identified one

00:02:33.880 --> 00:02:33.890
in my lab we've recently identified one
 

00:02:33.890 --> 00:02:36.310
in my lab we've recently identified one
of these regulatory genes for male

00:02:36.310 --> 00:02:36.320
of these regulatory genes for male
 

00:02:36.320 --> 00:02:38.890
of these regulatory genes for male
sexual development and we think that it

00:02:38.890 --> 00:02:38.900
sexual development and we think that it
 

00:02:38.900 --> 00:02:41.050
sexual development and we think that it
is not a relay for the master regulator

00:02:41.050 --> 00:02:41.060
is not a relay for the master regulator
 

00:02:41.060 --> 00:02:44.080
is not a relay for the master regulator
rather it regulates the on switch for

00:02:44.080 --> 00:02:44.090
rather it regulates the on switch for
 

00:02:44.090 --> 00:02:46.720
rather it regulates the on switch for
the master regulator we study the

00:02:46.720 --> 00:02:46.730
the master regulator we study the
 

00:02:46.730 --> 00:02:49.479
the master regulator we study the
populations of Jewish and Hispanic

00:02:49.479 --> 00:02:49.489
populations of Jewish and Hispanic
 

00:02:49.489 --> 00:02:52.180
populations of Jewish and Hispanic
Latino people together these groups

00:02:52.180 --> 00:02:52.190
Latino people together these groups
 

00:02:52.190 --> 00:02:54.520
Latino people together these groups
comprise twelve and twenty percent of

00:02:54.520 --> 00:02:54.530
comprise twelve and twenty percent of
 

00:02:54.530 --> 00:02:57.160
comprise twelve and twenty percent of
the population of New York City we're

00:02:57.160 --> 00:02:57.170
the population of New York City we're
 

00:02:57.170 --> 00:02:59.140
the population of New York City we're
tracing the Jewish Diaspora back and

00:02:59.140 --> 00:02:59.150
tracing the Jewish Diaspora back and
 

00:02:59.150 --> 00:03:01.060
tracing the Jewish Diaspora back and
forth across the Mediterranean Basin

00:03:01.060 --> 00:03:01.070
forth across the Mediterranean Basin
 

00:03:01.070 --> 00:03:04.810
forth across the Mediterranean Basin
into Europe and into the new world Jews

00:03:04.810 --> 00:03:04.820
into Europe and into the new world Jews
 

00:03:04.820 --> 00:03:06.520
into Europe and into the new world Jews
form their own distinctive genetic

00:03:06.520 --> 00:03:06.530
form their own distinctive genetic
 

00:03:06.530 --> 00:03:09.400
form their own distinctive genetic
clusters with each group of the Diaspora

00:03:09.400 --> 00:03:09.410
clusters with each group of the Diaspora
 

00:03:09.410 --> 00:03:12.400
clusters with each group of the Diaspora
forming its own sub cluster Puerto

00:03:12.400 --> 00:03:12.410
forming its own sub cluster Puerto
 

00:03:12.410 --> 00:03:14.020
forming its own sub cluster Puerto
Ricans and Dominicans are for the most

00:03:14.020 --> 00:03:14.030
Ricans and Dominicans are for the most
 

00:03:14.030 --> 00:03:16.360
Ricans and Dominicans are for the most
part the variable descendants of

00:03:16.360 --> 00:03:16.370
part the variable descendants of
 

00:03:16.370 --> 00:03:19.270
part the variable descendants of
Europeans and Africans whereas Mexicans

00:03:19.270 --> 00:03:19.280
Europeans and Africans whereas Mexicans
 

00:03:19.280 --> 00:03:21.520
Europeans and Africans whereas Mexicans
Ecuadorians and Colombians are the

00:03:21.520 --> 00:03:21.530
Ecuadorians and Colombians are the
 

00:03:21.530 --> 00:03:23.229
Ecuadorians and Colombians are the
descendants of Native Americans and

00:03:23.229 --> 00:03:23.239
descendants of Native Americans and
 

00:03:23.239 --> 00:03:25.990
descendants of Native Americans and
Europeans we're using methods that

00:03:25.990 --> 00:03:26.000
Europeans we're using methods that
 

00:03:26.000 --> 00:03:27.190
Europeans we're using methods that
recognize this

00:03:27.190 --> 00:03:27.200
recognize this
 

00:03:27.200 --> 00:03:30.010
recognize this
mixed ancestry to map genes for traits

00:03:30.010 --> 00:03:30.020
mixed ancestry to map genes for traits
 

00:03:30.020 --> 00:03:32.140
mixed ancestry to map genes for traits
such as susceptibility to breast cancer

00:03:32.140 --> 00:03:32.150
such as susceptibility to breast cancer
 

00:03:32.150 --> 00:03:35.920
such as susceptibility to breast cancer
in fact my nyu collaborators and i are

00:03:35.920 --> 00:03:35.930
in fact my nyu collaborators and i are
 

00:03:35.930 --> 00:03:38.080
in fact my nyu collaborators and i are
working to develop predictive genetic

00:03:38.080 --> 00:03:38.090
working to develop predictive genetic
 

00:03:38.090 --> 00:03:41.410
working to develop predictive genetic
tests for breast prostate and prostate

00:03:41.410 --> 00:03:41.420
tests for breast prostate and prostate
 

00:03:41.420 --> 00:03:45.820
tests for breast prostate and prostate
cancers as well as melanoma envisioning

00:03:45.820 --> 00:03:45.830
cancers as well as melanoma envisioning
 

00:03:45.830 --> 00:03:48.430
cancers as well as melanoma envisioning
a day perhaps five years hence when it

00:03:48.430 --> 00:03:48.440
a day perhaps five years hence when it
 

00:03:48.440 --> 00:03:50.350
a day perhaps five years hence when it
will be possible to perform a test in

00:03:50.350 --> 00:03:50.360
will be possible to perform a test in
 

00:03:50.360 --> 00:03:53.050
will be possible to perform a test in
which the results will be reproducible

00:03:53.050 --> 00:03:53.060
which the results will be reproducible
 

00:03:53.060 --> 00:03:56.020
which the results will be reproducible
in meaningful if we thought that the

00:03:56.020 --> 00:03:56.030
in meaningful if we thought that the
 

00:03:56.030 --> 00:03:57.670
in meaningful if we thought that the
tests that are offered by

00:03:57.670 --> 00:03:57.680
tests that are offered by
 

00:03:57.680 --> 00:03:59.830
tests that are offered by
direct-to-consumer genetic testing

00:03:59.830 --> 00:03:59.840
direct-to-consumer genetic testing
 

00:03:59.840 --> 00:04:02.259
direct-to-consumer genetic testing
companies were valid then we would use

00:04:02.259 --> 00:04:02.269
companies were valid then we would use
 

00:04:02.269 --> 00:04:03.970
companies were valid then we would use
them at our cancer genetics risk

00:04:03.970 --> 00:04:03.980
them at our cancer genetics risk
 

00:04:03.980 --> 00:04:06.880
them at our cancer genetics risk
evaluation program where we see nearly a

00:04:06.880 --> 00:04:06.890
evaluation program where we see nearly a
 

00:04:06.890 --> 00:04:09.370
evaluation program where we see nearly a
thousand people each year assessing

00:04:09.370 --> 00:04:09.380
thousand people each year assessing
 

00:04:09.380 --> 00:04:11.440
thousand people each year assessing
their risks of breast ovarian and colon

00:04:11.440 --> 00:04:11.450
their risks of breast ovarian and colon
 

00:04:11.450 --> 00:04:14.710
their risks of breast ovarian and colon
cancers when a new genetic test is

00:04:14.710 --> 00:04:14.720
cancers when a new genetic test is
 

00:04:14.720 --> 00:04:17.080
cancers when a new genetic test is
introduced into clinical practice we're

00:04:17.080 --> 00:04:17.090
introduced into clinical practice we're
 

00:04:17.090 --> 00:04:19.690
introduced into clinical practice we're
looking for three things analytical

00:04:19.690 --> 00:04:19.700
looking for three things analytical
 

00:04:19.700 --> 00:04:21.550
looking for three things analytical
validity clinical validity and clinical

00:04:21.550 --> 00:04:21.560
validity clinical validity and clinical
 

00:04:21.560 --> 00:04:24.909
validity clinical validity and clinical
utility the tests that are performed in

00:04:24.909 --> 00:04:24.919
utility the tests that are performed in
 

00:04:24.919 --> 00:04:27.490
utility the tests that are performed in
my clinical genetics laboratory and in

00:04:27.490 --> 00:04:27.500
my clinical genetics laboratory and in
 

00:04:27.500 --> 00:04:29.500
my clinical genetics laboratory and in
the other laboratories that I use to

00:04:29.500 --> 00:04:29.510
the other laboratories that I use to
 

00:04:29.510 --> 00:04:32.279
the other laboratories that I use to
assess the risk for my patients at NYU

00:04:32.279 --> 00:04:32.289
assess the risk for my patients at NYU
 

00:04:32.289 --> 00:04:36.279
assess the risk for my patients at NYU
meet all of these criteria let's look at

00:04:36.279 --> 00:04:36.289
meet all of these criteria let's look at
 

00:04:36.289 --> 00:04:39.430
meet all of these criteria let's look at
each of these in turn analytical

00:04:39.430 --> 00:04:39.440
each of these in turn analytical
 

00:04:39.440 --> 00:04:42.070
each of these in turn analytical
validity is the ability of a test to

00:04:42.070 --> 00:04:42.080
validity is the ability of a test to
 

00:04:42.080 --> 00:04:44.350
validity is the ability of a test to
accurately and reliably measure the

00:04:44.350 --> 00:04:44.360
accurately and reliably measure the
 

00:04:44.360 --> 00:04:47.920
accurately and reliably measure the
genotype of interest for many DNA chips

00:04:47.920 --> 00:04:47.930
genotype of interest for many DNA chips
 

00:04:47.930 --> 00:04:50.310
genotype of interest for many DNA chips
the call rates are in the range of 98 to

00:04:50.310 --> 00:04:50.320
the call rates are in the range of 98 to
 

00:04:50.320 --> 00:04:54.580
the call rates are in the range of 98 to
99.9 percent that sounds great but let's

00:04:54.580 --> 00:04:54.590
99.9 percent that sounds great but let's
 

00:04:54.590 --> 00:04:57.340
99.9 percent that sounds great but let's
throw in some numbers this means on a

00:04:57.340 --> 00:04:57.350
throw in some numbers this means on a
 

00:04:57.350 --> 00:05:00.550
throw in some numbers this means on a
DNA chip with the million probes 1,000

00:05:00.550 --> 00:05:00.560
DNA chip with the million probes 1,000
 

00:05:00.560 --> 00:05:02.820
DNA chip with the million probes 1,000
to 20,000 results are being missed

00:05:02.820 --> 00:05:02.830
to 20,000 results are being missed
 

00:05:02.830 --> 00:05:06.159
to 20,000 results are being missed
that's okay in my research lab but it

00:05:06.159 --> 00:05:06.169
that's okay in my research lab but it
 

00:05:06.169 --> 00:05:08.560
that's okay in my research lab but it
sure isn't in my clinical lab where I

00:05:08.560 --> 00:05:08.570
sure isn't in my clinical lab where I
 

00:05:08.570 --> 00:05:10.900
sure isn't in my clinical lab where I
have to guarantee to the patients into

00:05:10.900 --> 00:05:10.910
have to guarantee to the patients into
 

00:05:10.910 --> 00:05:12.940
have to guarantee to the patients into
the Department of Health that I can

00:05:12.940 --> 00:05:12.950
the Department of Health that I can
 

00:05:12.950 --> 00:05:14.890
the Department of Health that I can
provide complete results to every

00:05:14.890 --> 00:05:14.900
provide complete results to every
 

00:05:14.900 --> 00:05:17.650
provide complete results to every
patient now let's throw in the recent

00:05:17.650 --> 00:05:17.660
patient now let's throw in the recent
 

00:05:17.660 --> 00:05:19.629
patient now let's throw in the recent
computer software and we learn from

00:05:19.629 --> 00:05:19.639
computer software and we learn from
 

00:05:19.639 --> 00:05:21.879
computer software and we learn from
shrikant Monty who runs the DNA chip

00:05:21.879 --> 00:05:21.889
shrikant Monty who runs the DNA chip
 

00:05:21.889 --> 00:05:24.159
shrikant Monty who runs the DNA chip
core facility at Yale that the false

00:05:24.159 --> 00:05:24.169
core facility at Yale that the false
 

00:05:24.169 --> 00:05:27.190
core facility at Yale that the false
positive rate is one percent this is a

00:05:27.190 --> 00:05:27.200
positive rate is one percent this is a
 

00:05:27.200 --> 00:05:29.440
positive rate is one percent this is a
false positive rate anywhere on the chip

00:05:29.440 --> 00:05:29.450
false positive rate anywhere on the chip
 

00:05:29.450 --> 00:05:31.960
false positive rate anywhere on the chip
not in the probe for breast cancer or

00:05:31.960 --> 00:05:31.970
not in the probe for breast cancer or
 

00:05:31.970 --> 00:05:35.350
not in the probe for breast cancer or
type 2 diabetes my patients in the

00:05:35.350 --> 00:05:35.360
type 2 diabetes my patients in the
 

00:05:35.360 --> 00:05:38.469
type 2 diabetes my patients in the
Department of Health would say well dr.

00:05:38.469 --> 00:05:38.479
Department of Health would say well dr.
 

00:05:38.479 --> 00:05:40.510
Department of Health would say well dr.
Auster that just isn't good enough

00:05:40.510 --> 00:05:40.520
Auster that just isn't good enough
 

00:05:40.520 --> 00:05:44.260
Auster that just isn't good enough
so what about clinical validity this is

00:05:44.260 --> 00:05:44.270
so what about clinical validity this is
 

00:05:44.270 --> 00:05:46.719
so what about clinical validity this is
the ability of a test to detect or

00:05:46.719 --> 00:05:46.729
the ability of a test to detect or
 

00:05:46.729 --> 00:05:49.809
the ability of a test to detect or
predict the associated disorder it must

00:05:49.809 --> 00:05:49.819
predict the associated disorder it must
 

00:05:49.819 --> 00:05:54.399
predict the associated disorder it must
be great now why else would these

00:05:54.399 --> 00:05:54.409
be great now why else would these
 

00:05:54.409 --> 00:05:57.390
be great now why else would these
directing consumer companies be offering

00:05:57.390 --> 00:05:57.400
directing consumer companies be offering
 

00:05:57.400 --> 00:06:01.149
directing consumer companies be offering
testing to consumers Jeffrey Drazen the

00:06:01.149 --> 00:06:01.159
testing to consumers Jeffrey Drazen the
 

00:06:01.159 --> 00:06:02.559
testing to consumers Jeffrey Drazen the
editor the New England Journal of

00:06:02.559 --> 00:06:02.569
editor the New England Journal of
 

00:06:02.569 --> 00:06:05.140
editor the New England Journal of
Medicine has written even the ardent

00:06:05.140 --> 00:06:05.150
Medicine has written even the ardent
 

00:06:05.150 --> 00:06:07.240
Medicine has written even the ardent
proponents of genetic susceptibility

00:06:07.240 --> 00:06:07.250
proponents of genetic susceptibility
 

00:06:07.250 --> 00:06:09.070
proponents of genetic susceptibility
testing would argue it would agree that

00:06:09.070 --> 00:06:09.080
testing would argue it would agree that
 

00:06:09.080 --> 00:06:11.529
testing would argue it would agree that
for most diseases we are still at the

00:06:11.529 --> 00:06:11.539
for most diseases we are still at the
 

00:06:11.539 --> 00:06:13.629
for most diseases we are still at the
early stages of identifying the full

00:06:13.629 --> 00:06:13.639
early stages of identifying the full
 

00:06:13.639 --> 00:06:15.640
early stages of identifying the full
list of susceptibility associated

00:06:15.640 --> 00:06:15.650
list of susceptibility associated
 

00:06:15.650 --> 00:06:18.580
list of susceptibility associated
variance we know from research studies

00:06:18.580 --> 00:06:18.590
variance we know from research studies
 

00:06:18.590 --> 00:06:20.499
variance we know from research studies
that most common diseases diabetes

00:06:20.499 --> 00:06:20.509
that most common diseases diabetes
 

00:06:20.509 --> 00:06:23.290
that most common diseases diabetes
various cancers and heart disease are

00:06:23.290 --> 00:06:23.300
various cancers and heart disease are
 

00:06:23.300 --> 00:06:25.839
various cancers and heart disease are
caused by multiple gene variants acting

00:06:25.839 --> 00:06:25.849
caused by multiple gene variants acting
 

00:06:25.849 --> 00:06:28.080
caused by multiple gene variants acting
together and with environmental factors

00:06:28.080 --> 00:06:28.090
together and with environmental factors
 

00:06:28.090 --> 00:06:30.670
together and with environmental factors
the studies that are now identifying

00:06:30.670 --> 00:06:30.680
the studies that are now identifying
 

00:06:30.680 --> 00:06:32.680
the studies that are now identifying
these factors and their interactions are

00:06:32.680 --> 00:06:32.690
these factors and their interactions are
 

00:06:32.690 --> 00:06:36.010
these factors and their interactions are
only now being conducted in their

00:06:36.010 --> 00:06:36.020
only now being conducted in their
 

00:06:36.020 --> 00:06:38.020
only now being conducted in their
validation for clinical use will come

00:06:38.020 --> 00:06:38.030
validation for clinical use will come
 

00:06:38.030 --> 00:06:41.050
validation for clinical use will come
later as you will hear from a fellow

00:06:41.050 --> 00:06:41.060
later as you will hear from a fellow
 

00:06:41.060 --> 00:06:43.600
later as you will hear from a fellow
panelist no two companies can agree on

00:06:43.600 --> 00:06:43.610
panelist no two companies can agree on
 

00:06:43.610 --> 00:06:46.899
panelist no two companies can agree on
her risk of disease boggers who have

00:06:46.899 --> 00:06:46.909
her risk of disease boggers who have
 

00:06:46.909 --> 00:06:49.059
her risk of disease boggers who have
used direct-to-consumer genetic testing

00:06:49.059 --> 00:06:49.069
used direct-to-consumer genetic testing
 

00:06:49.069 --> 00:06:50.950
used direct-to-consumer genetic testing
have written about how their diabetes or

00:06:50.950 --> 00:06:50.960
have written about how their diabetes or
 

00:06:50.960 --> 00:06:53.290
have written about how their diabetes or
colon cancer was not predicted by the

00:06:53.290 --> 00:06:53.300
colon cancer was not predicted by the
 

00:06:53.300 --> 00:06:58.120
colon cancer was not predicted by the
DNA chip kenneth 'it the head of cancer

00:06:58.120 --> 00:06:58.130
DNA chip kenneth 'it the head of cancer
 

00:06:58.130 --> 00:06:59.680
DNA chip kenneth 'it the head of cancer
genetics at memorial sloan-kettering

00:06:59.680 --> 00:06:59.690
genetics at memorial sloan-kettering
 

00:06:59.690 --> 00:07:02.320
genetics at memorial sloan-kettering
Cancer Center has written the companies

00:07:02.320 --> 00:07:02.330
Cancer Center has written the companies
 

00:07:02.330 --> 00:07:05.019
Cancer Center has written the companies
offered often state that the services

00:07:05.019 --> 00:07:05.029
offered often state that the services
 

00:07:05.029 --> 00:07:08.350
offered often state that the services
offered are not medical tests but they

00:07:08.350 --> 00:07:08.360
offered are not medical tests but they
 

00:07:08.360 --> 00:07:10.120
offered are not medical tests but they
are provided for informational purposes

00:07:10.120 --> 00:07:10.130
are provided for informational purposes
 

00:07:10.130 --> 00:07:14.409
are provided for informational purposes
only but seriously folks if you learn

00:07:14.409 --> 00:07:14.419
only but seriously folks if you learn
 

00:07:14.419 --> 00:07:15.700
only but seriously folks if you learn
that you were at increased risk for

00:07:15.700 --> 00:07:15.710
that you were at increased risk for
 

00:07:15.710 --> 00:07:18.820
that you were at increased risk for
heart attack or colon cancer or type 2

00:07:18.820 --> 00:07:18.830
heart attack or colon cancer or type 2
 

00:07:18.830 --> 00:07:21.129
heart attack or colon cancer or type 2
diabetes wouldn't you want to discuss

00:07:21.129 --> 00:07:21.139
diabetes wouldn't you want to discuss
 

00:07:21.139 --> 00:07:23.379
diabetes wouldn't you want to discuss
this with your doctor it wouldn't you

00:07:23.379 --> 00:07:23.389
this with your doctor it wouldn't you
 

00:07:23.389 --> 00:07:25.779
this with your doctor it wouldn't you
feel rather foolish when he said but

00:07:25.779 --> 00:07:25.789
feel rather foolish when he said but
 

00:07:25.789 --> 00:07:28.510
feel rather foolish when he said but
seriously Ted let's not make too much

00:07:28.510 --> 00:07:28.520
seriously Ted let's not make too much
 

00:07:28.520 --> 00:07:31.360
seriously Ted let's not make too much
out of this or would he start ordering

00:07:31.360 --> 00:07:31.370
out of this or would he start ordering
 

00:07:31.370 --> 00:07:35.649
out of this or would he start ordering
tests a stress EKG colonoscopy a glucose

00:07:35.649 --> 00:07:35.659
tests a stress EKG colonoscopy a glucose
 

00:07:35.659 --> 00:07:38.050
tests a stress EKG colonoscopy a glucose
tolerance test to follow up on the false

00:07:38.050 --> 00:07:38.060
tolerance test to follow up on the false
 

00:07:38.060 --> 00:07:40.540
tolerance test to follow up on the false
positive results that are the bane of

00:07:40.540 --> 00:07:40.550
positive results that are the bane of
 

00:07:40.550 --> 00:07:44.110
positive results that are the bane of
physicians practices this raises the

00:07:44.110 --> 00:07:44.120
physicians practices this raises the
 

00:07:44.120 --> 00:07:46.600
physicians practices this raises the
third issue of clinical utility or the

00:07:46.600 --> 00:07:46.610
third issue of clinical utility or the
 

00:07:46.610 --> 00:07:49.290
third issue of clinical utility or the
balance of associated risks and benefits

00:07:49.290 --> 00:07:49.300
balance of associated risks and benefits
 

00:07:49.300 --> 00:07:51.339
balance of associated risks and benefits
Jeffrey Drazen from the New England

00:07:51.339 --> 00:07:51.349
Jeffrey Drazen from the New England
 

00:07:51.349 --> 00:07:53.740
Jeffrey Drazen from the New England
Journal has written this is the arena

00:07:53.740 --> 00:07:53.750
Journal has written this is the arena
 

00:07:53.750 --> 00:07:54.279
Journal has written this is the arena
and what

00:07:54.279 --> 00:07:54.289
and what
 

00:07:54.289 --> 00:07:56.980
and what
they're virtually no data on the health

00:07:56.980 --> 00:07:56.990
they're virtually no data on the health
 

00:07:56.990 --> 00:08:00.159
they're virtually no data on the health
impact of genome-wide analysis there are

00:08:00.159 --> 00:08:00.169
impact of genome-wide analysis there are
 

00:08:00.169 --> 00:08:02.260
impact of genome-wide analysis there are
very few observational studies and

00:08:02.260 --> 00:08:02.270
very few observational studies and
 

00:08:02.270 --> 00:08:04.420
very few observational studies and
almost no clinical trials that

00:08:04.420 --> 00:08:04.430
almost no clinical trials that
 

00:08:04.430 --> 00:08:05.739
almost no clinical trials that
demonstrate the risks and benefits

00:08:05.739 --> 00:08:05.749
demonstrate the risks and benefits
 

00:08:05.749 --> 00:08:09.459
demonstrate the risks and benefits
associated with screening for individual

00:08:09.459 --> 00:08:09.469
associated with screening for individual
 

00:08:09.469 --> 00:08:12.129
associated with screening for individual
gene variants let alone testing for many

00:08:12.129 --> 00:08:12.139
gene variants let alone testing for many
 

00:08:12.139 --> 00:08:14.589
gene variants let alone testing for many
hundreds of thousands of variants and

00:08:14.589 --> 00:08:14.599
hundreds of thousands of variants and
 

00:08:14.599 --> 00:08:17.200
hundreds of thousands of variants and
what might we do and what might those

00:08:17.200 --> 00:08:17.210
what might we do and what might those
 

00:08:17.210 --> 00:08:20.529
what might we do and what might those
recommendations be lose weight eat

00:08:20.529 --> 00:08:20.539
recommendations be lose weight eat
 

00:08:20.539 --> 00:08:24.040
recommendations be lose weight eat
better stop smoking exercise more who

00:08:24.040 --> 00:08:24.050
better stop smoking exercise more who
 

00:08:24.050 --> 00:08:26.049
better stop smoking exercise more who
needs a thousand-dollar genetic test to

00:08:26.049 --> 00:08:26.059
needs a thousand-dollar genetic test to
 

00:08:26.059 --> 00:08:28.510
needs a thousand-dollar genetic test to
tell her to engage in lifestyle changes

00:08:28.510 --> 00:08:28.520
tell her to engage in lifestyle changes
 

00:08:28.520 --> 00:08:30.839
tell her to engage in lifestyle changes
that will have broad health effects

00:08:30.839 --> 00:08:30.849
that will have broad health effects
 

00:08:30.849 --> 00:08:33.670
that will have broad health effects
suppose she learns she is at increased

00:08:33.670 --> 00:08:33.680
suppose she learns she is at increased
 

00:08:33.680 --> 00:08:36.100
suppose she learns she is at increased
risk for breast cancer as women who are

00:08:36.100 --> 00:08:36.110
risk for breast cancer as women who are
 

00:08:36.110 --> 00:08:39.579
risk for breast cancer as women who are
brca1 carriers do would she take drugs

00:08:39.579 --> 00:08:39.589
brca1 carriers do would she take drugs
 

00:08:39.589 --> 00:08:41.740
brca1 carriers do would she take drugs
that would put her into menopause or

00:08:41.740 --> 00:08:41.750
that would put her into menopause or
 

00:08:41.750 --> 00:08:43.389
that would put her into menopause or
have her breasts removed to lower the

00:08:43.389 --> 00:08:43.399
have her breasts removed to lower the
 

00:08:43.399 --> 00:08:46.420
have her breasts removed to lower the
risk would she just worry her way from

00:08:46.420 --> 00:08:46.430
risk would she just worry her way from
 

00:08:46.430 --> 00:08:50.559
risk would she just worry her way from
one mammogram to the next so what can we

00:08:50.559 --> 00:08:50.569
one mammogram to the next so what can we
 

00:08:50.569 --> 00:08:53.860
one mammogram to the next so what can we
do now that is reasonable get diagnosed

00:08:53.860 --> 00:08:53.870
do now that is reasonable get diagnosed
 

00:08:53.870 --> 00:08:56.650
do now that is reasonable get diagnosed
if you have a genetic disease get

00:08:56.650 --> 00:08:56.660
if you have a genetic disease get
 

00:08:56.660 --> 00:08:58.990
if you have a genetic disease get
treated and learn about it knowledge is

00:08:58.990 --> 00:08:59.000
treated and learn about it knowledge is
 

00:08:59.000 --> 00:09:02.079
treated and learn about it knowledge is
power learn about your family history if

00:09:02.079 --> 00:09:02.089
power learn about your family history if
 

00:09:02.089 --> 00:09:04.540
power learn about your family history if
based on your family history you are at

00:09:04.540 --> 00:09:04.550
based on your family history you are at
 

00:09:04.550 --> 00:09:06.420
based on your family history you are at
high risk for colon cancer heart disease

00:09:06.420 --> 00:09:06.430
high risk for colon cancer heart disease
 

00:09:06.430 --> 00:09:09.250
high risk for colon cancer heart disease
blood clots or host of other conditions

00:09:09.250 --> 00:09:09.260
blood clots or host of other conditions
 

00:09:09.260 --> 00:09:11.550
blood clots or host of other conditions
consult with the medical geneticist

00:09:11.550 --> 00:09:11.560
consult with the medical geneticist
 

00:09:11.560 --> 00:09:14.199
consult with the medical geneticist
there may be a specific genetic test

00:09:14.199 --> 00:09:14.209
there may be a specific genetic test
 

00:09:14.209 --> 00:09:17.410
there may be a specific genetic test
that is appropriate for you get carrot

00:09:17.410 --> 00:09:17.420
that is appropriate for you get carrot
 

00:09:17.420 --> 00:09:19.360
that is appropriate for you get carrot
carrier testing before marriage before

00:09:19.360 --> 00:09:19.370
carrier testing before marriage before
 

00:09:19.370 --> 00:09:22.930
carrier testing before marriage before
pregnancy during pregnancy get the other

00:09:22.930 --> 00:09:22.940
pregnancy during pregnancy get the other
 

00:09:22.940 --> 00:09:25.090
pregnancy during pregnancy get the other
tests that are appropriate for people in

00:09:25.090 --> 00:09:25.100
tests that are appropriate for people in
 

00:09:25.100 --> 00:09:28.210
tests that are appropriate for people in
your stage of the life cycle learn your

00:09:28.210 --> 00:09:28.220
your stage of the life cycle learn your
 

00:09:28.220 --> 00:09:30.790
your stage of the life cycle learn your
wrists and act you don't need a

00:09:30.790 --> 00:09:30.800
wrists and act you don't need a
 

00:09:30.800 --> 00:09:32.829
wrists and act you don't need a
thousand-dollar genetic test to spur you

00:09:32.829 --> 00:09:32.839
thousand-dollar genetic test to spur you
 

00:09:32.839 --> 00:09:35.800
thousand-dollar genetic test to spur you
into action now the purveyors of

00:09:35.800 --> 00:09:35.810
into action now the purveyors of
 

00:09:35.810 --> 00:09:37.929
into action now the purveyors of
direct-to-consumer genetic testing would

00:09:37.929 --> 00:09:37.939
direct-to-consumer genetic testing would
 

00:09:37.939 --> 00:09:40.079
direct-to-consumer genetic testing would
say that this is the old fashioned

00:09:40.079 --> 00:09:40.089
say that this is the old fashioned
 

00:09:40.089 --> 00:09:42.699
say that this is the old fashioned
neanderthal what I'd practice of medical

00:09:42.699 --> 00:09:42.709
neanderthal what I'd practice of medical
 

00:09:42.709 --> 00:09:47.139
neanderthal what I'd practice of medical
genetics but I would beg to differ we

00:09:47.139 --> 00:09:47.149
genetics but I would beg to differ we
 

00:09:47.149 --> 00:09:48.639
genetics but I would beg to differ we
medical geneticists and genetic

00:09:48.639 --> 00:09:48.649
medical geneticists and genetic
 

00:09:48.649 --> 00:09:52.329
medical geneticists and genetic
counselors are the age of progress of

00:09:52.329 --> 00:09:52.339
counselors are the age of progress of
 

00:09:52.339 --> 00:09:55.449
counselors are the age of progress of
genetic discovery we have reinvented our

00:09:55.449 --> 00:09:55.459
genetic discovery we have reinvented our
 

00:09:55.459 --> 00:09:57.790
genetic discovery we have reinvented our
profession many times and we are leading

00:09:57.790 --> 00:09:57.800
profession many times and we are leading
 

00:09:57.800 --> 00:10:00.189
profession many times and we are leading
the way to discovering the analytical

00:10:00.189 --> 00:10:00.199
the way to discovering the analytical
 

00:10:00.199 --> 00:10:02.530
the way to discovering the analytical
validity the clinical validity and the

00:10:02.530 --> 00:10:02.540
validity the clinical validity and the
 

00:10:02.540 --> 00:10:06.040
validity the clinical validity and the
clinical utility of new genetic tests we

00:10:06.040 --> 00:10:06.050
clinical utility of new genetic tests we
 

00:10:06.050 --> 00:10:08.199
clinical utility of new genetic tests we
admire the community activism

00:10:08.199 --> 00:10:08.209
admire the community activism
 

00:10:08.209 --> 00:10:09.939
admire the community activism
that brought us new treatments for

00:10:09.939 --> 00:10:09.949
that brought us new treatments for
 

00:10:09.949 --> 00:10:13.030
that brought us new treatments for
hiv/aids expanded genetic screening for

00:10:13.030 --> 00:10:13.040
hiv/aids expanded genetic screening for
 

00:10:13.040 --> 00:10:15.600
hiv/aids expanded genetic screening for
breast cancer via mammography and

00:10:15.600 --> 00:10:15.610
breast cancer via mammography and
 

00:10:15.610 --> 00:10:18.460
breast cancer via mammography and
validated new genetic testing for many

00:10:18.460 --> 00:10:18.470
validated new genetic testing for many
 

00:10:18.470 --> 00:10:21.669
validated new genetic testing for many
conditions we want to build a bridge to

00:10:21.669 --> 00:10:21.679
conditions we want to build a bridge to
 

00:10:21.679 --> 00:10:23.919
conditions we want to build a bridge to
somewhere we're looking forward to that

00:10:23.919 --> 00:10:23.929
somewhere we're looking forward to that
 

00:10:23.929 --> 00:10:26.619
somewhere we're looking forward to that
day when a 61 year old man walks into

00:10:26.619 --> 00:10:26.629
day when a 61 year old man walks into
 

00:10:26.629 --> 00:10:29.230
day when a 61 year old man walks into
our office with a pill rolling trimmer

00:10:29.230 --> 00:10:29.240
our office with a pill rolling trimmer
 

00:10:29.240 --> 00:10:32.679
our office with a pill rolling trimmer
and we can insert his DNA sequence micro

00:10:32.679 --> 00:10:32.689
and we can insert his DNA sequence micro
 

00:10:32.689 --> 00:10:36.429
and we can insert his DNA sequence micro
disk into our genetic risk reader and it

00:10:36.429 --> 00:10:36.439
disk into our genetic risk reader and it
 

00:10:36.439 --> 00:10:38.710
disk into our genetic risk reader and it
will stay with high likelihood that he

00:10:38.710 --> 00:10:38.720
will stay with high likelihood that he
 

00:10:38.720 --> 00:10:42.759
will stay with high likelihood that he
has Parkinson disease type 7 moreover it

00:10:42.759 --> 00:10:42.769
has Parkinson disease type 7 moreover it
 

00:10:42.769 --> 00:10:44.319
has Parkinson disease type 7 moreover it
will tell us that he would benefit from

00:10:44.319 --> 00:10:44.329
will tell us that he would benefit from
 

00:10:44.329 --> 00:10:47.109
will tell us that he would benefit from
treatment with drug see because of his

00:10:47.109 --> 00:10:47.119
treatment with drug see because of his
 

00:10:47.119 --> 00:10:50.739
treatment with drug see because of his
personal risk benefit genetic ratio that

00:10:50.739 --> 00:10:50.749
personal risk benefit genetic ratio that
 

00:10:50.749 --> 00:10:53.109
personal risk benefit genetic ratio that
day is not far off and it will be coming

00:10:53.109 --> 00:10:53.119
day is not far off and it will be coming
 

00:10:53.119 --> 00:10:56.619
day is not far off and it will be coming
one disease at a time in the meantime I

00:10:56.619 --> 00:10:56.629
one disease at a time in the meantime I
 

00:10:56.629 --> 00:10:58.239
one disease at a time in the meantime I
fear that the purveyors of

00:10:58.239 --> 00:10:58.249
fear that the purveyors of
 

00:10:58.249 --> 00:11:01.150
fear that the purveyors of
direct-to-consumer genetic testing where

00:11:01.150 --> 00:11:01.160
direct-to-consumer genetic testing where
 

00:11:01.160 --> 00:11:03.040
direct-to-consumer genetic testing where
their faulty claims will scare away our

00:11:03.040 --> 00:11:03.050
their faulty claims will scare away our
 

00:11:03.050 --> 00:11:05.139
their faulty claims will scare away our
patients and betray the public's trust

00:11:05.139 --> 00:11:05.149
patients and betray the public's trust
 

00:11:05.149 --> 00:11:07.780
patients and betray the public's trust
in medical genetics thank you very much

00:11:07.780 --> 00:11:07.790
in medical genetics thank you very much
 

00:11:07.790 --> 00:11:10.209
in medical genetics thank you very much
for listening

